|
ES2539045T3
(es)
*
|
2009-01-19 |
2015-06-25 |
Innate Pharma |
Anticuerpos anti-KIR3D
|
|
RU2682449C2
(ru)
|
2012-09-19 |
2019-03-19 |
Иннейт Фарма |
Связывающие kir3dl2 агенты
|
|
DK2958941T3
(da)
|
2013-02-20 |
2019-06-24 |
Innate Pharma |
Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom
|
|
US10280222B2
(en)
*
|
2014-03-14 |
2019-05-07 |
Innate Pharma |
Humanized antibodies with increased stability
|
|
JP6822849B2
(ja)
|
2014-06-27 |
2021-01-27 |
イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． |
多重特異的ＮＫｐ４６結合タンパク質
|
|
CA2952532A1
(en)
|
2014-06-27 |
2015-12-30 |
Innate Pharma |
Multispecific antigen binding proteins
|
|
WO2016030488A1
(en)
*
|
2014-08-27 |
2016-03-03 |
Innate Pharma |
Treatment of celiac disease
|
|
CA2988912C
(en)
|
2015-06-10 |
2023-09-12 |
National Research Council Of Canada |
Carbonic anhydrase ix-specific antibodies and uses thereof
|
|
DK3313876T3
(da)
|
2015-06-23 |
2025-04-22 |
Innate Pharma |
Multispecifikke antigenbindende proteiner
|
|
WO2016207278A1
(en)
|
2015-06-23 |
2016-12-29 |
Innate Pharma |
Multispecific nk engager proteins
|
|
WO2017156423A2
(en)
*
|
2016-03-11 |
2017-09-14 |
Integrated Biotherapeutics, Inc. |
Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever
|
|
US10858431B2
(en)
*
|
2016-06-30 |
2020-12-08 |
Trellis Bioscience, Llc |
Monoclonal antibodies targeting killer immunoglobulin-like receptor (KIR) family signaling
|
|
US20190248895A1
(en)
*
|
2016-10-21 |
2019-08-15 |
Innate Pharma |
Treatment with anti-kir3dl2 agents
|
|
WO2018115262A1
(en)
|
2016-12-23 |
2018-06-28 |
Innate Pharma |
Heterodimeric antigen binding proteins
|
|
EP3579879A4
(en)
*
|
2017-02-09 |
2020-12-16 |
Memorial Sloan Kettering Cancer Center |
ANTI-BODY ANTI-KIR3DL1
|
|
EP3630182A4
(en)
*
|
2017-05-24 |
2021-02-24 |
Development Center for Biotechnology |
HUMANIZED ANTIBODIES TO GLOBO H AND THEIR USE IN CANCER TREATMENT
|
|
JP7264831B2
(ja)
*
|
2017-06-15 |
2023-04-25 |
ディベロップメント センター フォー バイオテクノロジー |
抗ｇｌｏｂｏ ｈ抗体を含有する抗体－薬物コンジュゲートおよびその使用
|
|
TWI789399B
(zh)
*
|
2017-06-22 |
2023-01-11 |
財團法人生物技術開發中心 |
不對稱異二聚fc-scfv融合抗globo h及抗cd3雙特異性抗體及其於癌症治療上之用途
|
|
AU2018371114A1
(en)
|
2017-11-21 |
2020-05-07 |
Innate Pharma |
Multispecific antigen binding proteins
|
|
US11560421B2
(en)
*
|
2018-02-09 |
2023-01-24 |
Osaka University |
Broad-spectrum monoclonal antibodies against chikungunya virus E1 structural protein
|
|
WO2020035345A1
(en)
|
2018-08-14 |
2020-02-20 |
Innate Pharma |
Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody
|
|
CA3125945A1
(en)
|
2019-01-22 |
2020-07-30 |
Innate Pharma |
Treatment of t cell lymphoma
|
|
CN114867493B
(zh)
|
2019-10-04 |
2026-04-10 |
阿尔伯特爱因斯坦医学院 |
Kir3dl3是免疫系统的抑制性受体及其用途
|
|
CN110950960B
(zh)
*
|
2019-11-26 |
2021-05-14 |
中国农业大学 |
基于高通量测序和杂合杂交瘤技术的小分子化合物抗体的制备方法
|
|
US20230119066A1
(en)
*
|
2020-03-23 |
2023-04-20 |
Bristol-Myers Squibb Company |
Anti-ccr8 antibodies for treating cancer
|
|
CN113817052A
(zh)
*
|
2020-06-19 |
2021-12-21 |
南京金斯瑞生物科技有限公司 |
抗SARS-CoV-2核衣壳蛋白单克隆抗体及其制备方法和用途
|
|
US20240101673A1
(en)
|
2021-02-03 |
2024-03-28 |
Mozart Therapeutics, Inc. |
Binding agents and methods of using the same
|
|
MX2023011310A
(es)
|
2021-03-26 |
2023-10-05 |
Innate Pharma |
Anclajes de citocina para proteinas de celulas nk de union a nkp46.
|
|
JP2024513880A
(ja)
|
2021-04-05 |
2024-03-27 |
イナート・ファルマ・ソシエテ・アノニム |
免疫組織化学法およびｋｉｒ３ｄｌ２特異的薬剤
|
|
WO2022258691A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
|
|
BR112023025331A2
(pt)
|
2021-06-09 |
2024-02-27 |
Innate Pharma |
Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
|
|
WO2022258678A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
|
|
US20250002601A1
(en)
|
2021-06-09 |
2025-01-02 |
Innate Pharma |
Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2
|
|
CN113248609B
(zh)
*
|
2021-07-14 |
2021-09-10 |
深圳市盛波尔生命科学技术有限责任公司 |
针对再生胰岛衍生蛋白1α的抗体组合以及包含其的检测试剂盒
|
|
WO2023009759A2
(en)
*
|
2021-07-30 |
2023-02-02 |
R.P. Scherer Technologies, Llc |
Antibody-drug conjugates and methods of use thereof
|
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
|
AU2023342647A1
(en)
|
2022-09-15 |
2025-02-20 |
Avidicure Ip B.V. |
Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
|
|
WO2024251884A1
(en)
|
2023-06-09 |
2024-12-12 |
Innate Pharma |
Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
|
|
CN117801108B
(zh)
*
|
2023-12-06 |
2024-06-07 |
无锡傲锐东源生物科技有限公司 |
抗人mdm2蛋白单克隆抗体及其杂交瘤细胞株和应用
|
|
WO2025191136A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
|
|
WO2025191137A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Conjugates of trop2-specific antigen binding proteins and cytokines
|
|
WO2025191133A1
(en)
|
2024-03-15 |
2025-09-18 |
Avidicure Ip B.V. |
Il-21 muteins, fusion proteins comprising the same and uses thereof
|
|
WO2025245386A1
(en)
*
|
2024-05-23 |
2025-11-27 |
La Jolla Institute For Immunology |
Kir3dl2 as an anti-cancer target
|